Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen +3 more
wiley +1 more source
Discovery of a First‐in‐Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity
Angewandte Chemie, Volume 138, Issue 7, 9 February 2026.A covalent allosteric inhibitor M029 was discovered for SHP1, a novel target for immunotherapy. M029 binds to a cryptic Cys remote from the active site, exhibits robust target engagement, and blocks tumor progression by stimulating antitumor immune response.
Zihan Qu +16 more
wiley +2 more sources
Navigating the Therapeutic Pathway and Optimal First-Line Systemic Therapy for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors. [PDF]
Medicina (Kaunas)Shin HP, Lee M.
europepmc +1 more source
Tui Na Acupressure Modulates Treg Immunosuppression via FoxP3/mTORC1 Signalling in ALS Mice
Immunology, Volume 177, Issue 3, Page 481-500, March 2026.The proposed mechanism by which Tui Na acupressure improves motor and cognitive dysfunction in ALS mice by activating the FoxP3/mTORC1 pathway. ABSTRACT Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease driven by neuroinflammation, where regulatory T cell (Treg) dysfunction exacerbates immune imbalance.
Jie Han +7 more
wiley +1 more source
A Systematic Review of Ipilimumab-Induced Hypophysitis. [PDF]
Endocr ConnectKim S +6 more
europepmc +1 more source
The Application of PD‐1 Inhibitors in Immunotherapy for Glioblastoma
The FASEB Journal, Volume 40, Issue 4, 28 February 2026.The molecular mechanism of PD‐1. When PD‐1 binds to PD‐L1, the ITIM and ITSM domains within PD‐1 are phosphorylated and subsequently recruit SHP‐2. This then dephosphorylates downstream molecules of the TCR, such as PI3K/AKT and ZAP70, reduces the secretion of IFN‐γ, and inhibits the presentation of antigens to T cells via MHC molecules through the ...
Ming‐zhen Dong +4 more
wiley +1 more source
Immune checkpoint inhibitor-associated diabetes mellitus: mechanisms, clinical manifestations, and management strategies. [PDF]
Front Endocrinol (Lausanne)Chen Y, Wang X, Duan S.
europepmc +1 more source
Immune Checkpoint Signatures in Minimal Change Disease and Membranous Nephropathy: Divergent Pathways of a Shared Imbalance. [PDF]
Int J Mol SciMertowski S +5 more
europepmc +1 more source
Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. [PDF]
Front ImmunolWang X, He J, Ding G, Tang Y, Wang Q.
europepmc +1 more source
Advanced Science, Volume 13, Issue 9, 13 February 2026.This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao +13 more
wiley +1 more source